An observational study in Prostate Cancer (Post Prostatectomy), Urinary Continence and Retzius-sparing Robot-assisted Radical Prostatectomy, sponsored by First Affiliated Hospital of Fujian Medical University. Active, not recruiting at 1 site in China. Open to male participants. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by First Affiliated Hospital of Fujian Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University — 10 open to participants now, 13 under way, 1 of them phase 3. Prostatic Neoplasms · First Affiliated Hospital of Fujian Medical University.
Among the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, this one is one of 6 that started in 2025, is one of 2 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 5th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →10 of the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University are open now, in 1 country. Recruiting first, the newest first:
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18–90 · Men only
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18–80 · Men only
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 30–85 · Men only
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18–90 · Men only
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18–80 · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 1
First in 2020; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 40 across the 13 interventional studies, 300 across the 2 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
First Affiliated Hospital of Fujian Medical University is the lead sponsor of 97 studies on the registry; 55 are open to participants now.
6 of the studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363382First Affiliated Hospital of Fujian Medical UniversityThe Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | 2026-12-31 |
| NCT07363486First Affiliated Hospital of Fujian Medical UniversitySequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06977906First Affiliated Hospital of Fujian Medical UniversityImproved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes | 2027-01-01 |
| NCT06850116First Affiliated Hospital of Fujian Medical UniversityAnalysis of Immediate Urinary Continence Predictors After RS-RARP | 2027-01-01 |
| NCT07056790First Affiliated Hospital of Fujian Medical UniversityResearch on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a retrospective, single-center clinical trial. It aims to retrospectively analyze the immediate postoperative urinary continence recovery in prostate cancer patients who underwent Retzius-sparing robot-assisted radical prostatectomy in the investigators' center. Based on the general conditions of patients, relevant perioperative clinical indicators, and parameters related to the sphincter and prostate gland measured by MRI, it explores the influencing factors of immediate urinary continence recovery after Retzius-sparing robot-assisted radical prostatectomy in prostate cancer patients and constructs a relevant prediction model, thereby providing clinical guidance value for predicting immediate postoperative urinary continence recovery.
Prostate cancer patients underwent RS-RARP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In 2010, Italian urologist Dr Bocciardi carried out the first clinical practice of separation and resection of the prostate via the vesicorectal fossa, and this new surgical procedure was called Retzius-sparing Robotic Assisted Radical Prostatectomy (RS-RARP). In recent years, the posterior approach extrafascial technique of RS-RARP which has been used to widely resect the prostate and its surrounding fascia and neurovascular bundles, compared with RS-RARP, has been proposed to provide more complete resection of the tumour and reduce the rate of positive margins. The patients are included into the Retzius-sparing robot-assisted radical prostatectomy group group who undergo the posterior approach extrafascial technique of RS-RARP.
Procedure: Retzius-sparing robot-assisted radical prostatectomy
Retzius-sparing robot-assisted radical prostatectomy
rate of continence
Time Frame: 1 week after postoperative removal of the urinary catheter
Time frame: rate of the preservation of urinary control function at 1 week after postoperative removal of the urinary catheter status
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Fujian Medical University